Yescarta® Now Approved in Japan for Initial Treatment of Relapsed/Refractory Large B-Cell LymphomaBusiness Wire • 12/22/22
Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIVBusiness Wire • 12/22/22
Arcus Biosciences, Gilead Sciences shares fall as new lung cancer drug data fails to meet investor expectationsProactive Investors • 12/20/22
Arcus Biosciences, Gilead shares are down after sharing data about new lung cancer drugMarket Watch • 12/20/22
Kite to Acquire Tmunity Therapeutics to Pursue Next Generation CAR T-Cell Therapy Advancements in CancerBusiness Wire • 12/20/22
Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer StudyBusiness Wire • 12/19/22
New Analyses of Kite's Tecartus® CAR T-Cell Therapy Provide Additional Evidence Supporting Overall Survival and Durability of ResponseBusiness Wire • 12/12/22
Three-Year Follow-Up Analysis of Kite's Yescarta® CAR T-cell Therapy (ZUMA-5 Trial) - 52% of Patients With Indolent Lymphomas Continued to Have Ongoing Responses at a Median Follow-Up of 40.5 MonthsBusiness Wire • 12/12/22
Body of Evidence Grows From ZUMA-7 Study Supporting Initial Treatment With Kite's Yescarta® CAR T-cell Therapy for Patients With Relapsed or Refractory Large B-cell LymphomaBusiness Wire • 12/11/22
Time to CAR T-cell Therapy May Impact Outcomes for Patients With Relapsed/Refractory Large B-cell Lymphoma in New CIBMTR AnalysisBusiness Wire • 12/11/22
Top-Notch IPO Stock Arcellx Breaks Out On $325 Million Cancer Tie-Up With Gilead SciencesInvestors Business Daily • 12/09/22
Arcellx flies on $325M deal with Gilead's Kite for multiple myeloma treatmentProactive Investors • 12/09/22